Psoriasis Global Market Report 2025

Description

Psoriasis is a skin condition characterized by the development of a rash with itchy, scaly patches, typically affecting areas such as the knees, elbows, trunk, and scalp. The underlying cause is often related to an immune system dysfunction where infection-fighting cells mistakenly attack healthy skin cells.

The primary categories of drugs used to manage psoriasis include interleukin inhibitors, corticosteroids, anti-inflammatories, and tumor necrosis factor inhibitors. Corticosteroids are a group of steroid hormones produced by the adrenal cortex in vertebrates and can also be synthesized as medications. These drugs come in various forms, including small molecules and biologics, and are applied to treat different manifestations of the disease, such as plaque psoriasis, nail psoriasis, guttate psoriasis, pustular psoriasis, and erythrodermic psoriasis. They are administered via various routes, including oral, topical, and injectable methods and can be obtained through hospitals, retail pharmacies, and e-commerce channels.

The psoriasis market research report is one of a series of new reports from The Business Research Company that provides psoriasis market statistics, including psoriasis industry global market size, regional shares, competitors with a psoriasis market share, detailed psoriasis market segments, market trends, and opportunities, and any further data you may need to thrive in the psoriasis industry. This psoriasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The psoriasis market size has grown rapidly in recent years. It will grow from $26.56 billion in 2024 to $29.5 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to epidemiology, patient awareness and education, healthcare infrastructure and access.

The psoriasis market size is expected to see strong growth in the next few years. It will grow to $42.34 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to regulatory approvals, patient preferences, aging population, increased awareness, introduction of novel therapies. Major trends in the forecast period include advancements in research and development, biologics and targeted therapies, oral small molecule therapies, personalized medicine, telemedicine and digital health, patient-centric care, biosimilars, artificial intelligence and machine learning.

The increasing prevalence of psoriasis patients is a driving force behind the growth of the psoriasis market. Psoriasis, a skin condition, is influenced by factors such as the immune system, genetics, and environmental factors. Over recent years, the surge in psoriasis cases can be primarily attributed to climate changes, elevated stress levels, and unhealthy lifestyles. The World Psoriasis Day consortium reports that a significant 2 to 3% of the global population, which translates to 125 million individuals, suffers from psoriasis. Consequently, the escalating number of psoriasis patients is expected to be a key driver for the growth of the psoriasis market in the foreseeable future.

The growing geriatric population is anticipated to drive the expansion of the psoriasis market in the coming years. The geriatric population comprises individuals aged 65 and older. This demographic has a significantly higher prevalence of conditions such as hypertension, diabetes mellitus, and elevated blood glucose levels, which can exacerbate psoriasis symptoms. For example, in January 2022, the Congressional Budget Office, a US-based federal agency, reported that the population eligible for Social Security payroll taxes and benefits is projected to increase from 342 million in 2024 to 383 million by 2054. This rise is primarily attributed to the substantial growth of the 65-and-older age group, contributing to an aging population. As a result, the increasing geriatric population is driving the growth of the social assistance market.

An emerging trend in the psoriasis market is the use of combination therapy. Combination therapy involves the simultaneous use of two different psoriasis treatments. Combining drugs with distinct mechanisms of action (combination therapy) often results in more significant treatment effects compared to monotherapy (using a single drug). Studies indicate that combination therapy provides more effective relief from psoriasis symptoms and is associated with fewer side effects. An example of combination therapy for treating active Psoriatic Arthritis (PsA) is the combination of Taltz (ixekizumab) with methotrexate, a development by Eli Lilly and Company.

Major companies operating in the psoriasis market are intensifying their efforts to introduce innovative products and secure approval from regulatory agencies, aiming to maximize their market revenues. The drug development and approval process is intricate and time-consuming, requiring drug sponsors to navigate the regulatory framework and marketing pathways to ensure safety and effectiveness. As an illustration, in September 2022, Boehringer Ingelheim, a Germany-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for SPEVIGO, marking the first approved treatment for generalized pustular psoriasis (GPP) flare-ups in adults. SPEVIGO is a novel, highly selective antibody designed to inhibit the interleukin-36 receptor (IL-36R) activation, a pivotal component of an immune system signaling pathway linked to GPP development. GPP, characterized by periods of widespread eruptions of sterile pustules, is a rare and potentially life-threatening neutrophilic skin condition.

The process of approving psoriasis drugs has become more streamlined on a global scale, as evidenced by the increasing approvals of drugs for psoriasis in recent years. Some notable examples include the regulatory approval of SKYRIZI (risankizumab) for plaque psoriasis treatment in Japan and the Center for Drug Evaluation and Research's approval of Avsola (infliximab-axxq) for treating plaque psoriasis. This simplified drug approval process is expected to drive the psoriasis drugs market in the forecast period.

Major companies operating in the psoriasis market include AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Celgene Corporation, Johnson & Johnson, Amgen Inc., Boehringer Ingelheim GmbH, Merck & Co. Inc., Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Stiefel Laboratories Inc., AstraZeneca Inc., Union Chimique Belge SA, Sun Pharmaceutical Industries Ltd., Forward Pharma AS, Almirall SA, Bausch Health Companies Inc., Biogen Inc., Biocon Biopharmaceuticals Pvt. Ltd., Celltrion Inc., Dr.Reddy's Laboratories Inc., Arcutis Biotherapeutics Inc., Bayer AG, Bristol Myers Squibb Co., Dermira Inc., Galderma SA, GlaxoSmithKline PLC, Incyte Pharmaceuticals Corp., LEO Pharmacy

North America was the largest region in the psoriasis market in 2024. Middle East is expected to be the fastest-growing region in the psoriasis market during the forecast period. The regions covered in the psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the psoriasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The psoriasis market consists of sales of Methotrexate, Ciclosporin, and Acitretin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Psoriasis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on psoriasis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for psoriasis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The psoriasis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug class: Interleukin Inhibitors; Corticosteroids; Anti-Inflammatory; Tumor Necrosis Factor Inhibitor
2) By Drug Types: Small molecules; Biologics
3) By Disease Indication: Plaque Psoriasis; Nail Psoriasis; Guttate Psoriasis; Pustular Psoriasis; Erythrodermic Psoriasis
4) By Route Of Administration: Oral; Tropical; Injectable
5) By Distribution Channel: Hospitals; Retail Pharmacies; E-Commerce
Subsegments:
1) By Interleukin Inhibitors: IL-12/23 Inhibitors (Ustekinumab); IL-17 Inhibitors (Secukinumab, Ixekizumab)
2) By Corticosteroids: Topical Corticosteroids (Hydrocortisone, Betamethasone); Systemic Corticosteroids (Prednisone)
3) By Anti-Inflammatory: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Biologic Anti-Inflammatory Agents (Apremilast)
4) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab (Humira); Etanercept (Enbrel); Infliximab (Remicade)
Companies Mentioned: AbbVie Inc.; Pfizer Inc.; Novartis AG; Eli Lilly and Company; Celgene Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r32742

1. Executive Summary

2. Psoriasis Market Characteristics

3. Psoriasis Market Trends And Strategies

4. Psoriasis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Psoriasis Growth Analysis And Strategic Analysis Framework

5.1. Global Psoriasis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Psoriasis Market Growth Rate Analysis
5.4. Global Psoriasis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Psoriasis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Psoriasis Total Addressable Market (TAM)

6. Psoriasis Market Segmentation

6.1. Global Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interleukin Inhibitors
Corticosteroids
Anti-Inflammatory
Tumor Necrosis Factor Inhibitor
6.2. Global Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small molecules
Biologics
6.3. Global Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plaque Psoriasis
Nail Psoriasis
Guttate Psoriasis
Pustular Psoriasis
Erythrodermic Psoriasis
6.4. Global Psoriasis Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Tropical
Injectable
6.5. Global Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Retail Pharmacies
E-Commerce
6.6. Global Psoriasis Market, Sub-Segmentation Of Interleukin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
IL-12/23 Inhibitors (Ustekinumab)
IL-17 Inhibitors (Secukinumab, Ixekizumab)
6.7. Global Psoriasis Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Topical Corticosteroids (Hydrocortisone, Betamethasone)
Systemic Corticosteroids (Prednisone)
6.8. Global Psoriasis Market, Sub-Segmentation Of Anti-Inflammatory, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Biologic Anti-Inflammatory Agents (Apremilast)
6.9. Global Psoriasis Market, Sub-Segmentation Of Tumor Necrosis Factor (TNF) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adalimumab (Humira)
Etanercept (Enbrel)
Infliximab (Remicade)

7. Psoriasis Market Regional And Country Analysis

7.1. Global Psoriasis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Psoriasis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Psoriasis Market

8.1. Asia-Pacific Psoriasis Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Psoriasis Market

9.1. China Psoriasis Market Overview
9.2. China Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Psoriasis Market

10.1. India Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Psoriasis Market

11.1. Japan Psoriasis Market Overview
11.2. Japan Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Psoriasis Market

12.1. Australia Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Psoriasis Market

13.1. Indonesia Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Psoriasis Market

14.1. South Korea Psoriasis Market Overview
14.2. South Korea Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Psoriasis Market

15.1. Western Europe Psoriasis Market Overview
15.2. Western Europe Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Psoriasis Market

16.1. UK Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Psoriasis Market

17.1. Germany Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Psoriasis Market

18.1. France Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Psoriasis Market

19.1. Italy Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Psoriasis Market

20.1. Spain Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Psoriasis Market

21.1. Eastern Europe Psoriasis Market Overview
21.2. Eastern Europe Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Psoriasis Market

22.1. Russia Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Psoriasis Market

23.1. North America Psoriasis Market Overview
23.2. North America Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Psoriasis Market

24.1. USA Psoriasis Market Overview
24.2. USA Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Psoriasis Market

25.1. Canada Psoriasis Market Overview
25.2. Canada Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Psoriasis Market

26.1. South America Psoriasis Market Overview
26.2. South America Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Psoriasis Market

27.1. Brazil Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Psoriasis Market

28.1. Middle East Psoriasis Market Overview
28.2. Middle East Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Psoriasis Market

29.1. Africa Psoriasis Market Overview
29.2. Africa Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Psoriasis Market Competitive Landscape And Company Profiles

30.1. Psoriasis Market Competitive Landscape
30.2. Psoriasis Market Company Profiles
- 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Celgene Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Psoriasis Market Other Major And Innovative Companies

31.1. Johnson & Johnson
31.2. Amgen Inc.
31.3. Boehringer Ingelheim GmbH
31.4. Merck & Co. Inc.
31.5. Janssen Biotech Inc.
31.6. Takeda Pharmaceutical Company Limited
31.7. Stiefel Laboratories Inc.
31.8. AstraZeneca Inc.
31.9. Union Chimique Belge SA
31.10. Sun Pharmaceutical Industries Ltd.
31.11. Forward Pharma AS
31.12. Almirall SA
31.13. Bausch Health Companies Inc.
31.14. Biogen Inc.
31.15. Biocon Biopharmaceuticals Pvt. Ltd.

32. Global Psoriasis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Psoriasis Market

34. Recent Developments In The Psoriasis Market

35. Psoriasis Market High Potential Countries, Segments and Strategies

35.1 Psoriasis Market In 2029 - Countries Offering Most New Opportunities
35.2 Psoriasis Market In 2029 - Segments Offering Most New Opportunities
35.3 Psoriasis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer